FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/03/2026
Voltar para busca
Dado oficial do USPTO
HARNESS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
35
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42
Data de depósito
19/02/2024
Data de registro
19/08/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/08/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
KEENAN, CAYLA FAY
Unidade examinadora
N40
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Harness Therapeutics Limited
Representantes
Rebecca Liebowitz Venable LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for scientific purposes; chemicals for use in scientific research; chemicalsenzymesbiological preparations in the nature of DNA and RNA for scientific research use; chemicals for scientific research use in the preparation and creation of DNA and RNA; enzymes for scientific research purposes for use in the preparation and creation of DNA and RNA; molecular biology research tools in the nature of biologicalchemical and biochemical reagents for research use
Classe 5
Pharmaceutical preparations for the treatment and prevention of ophthalmological conditionshearing losshematologic diseasesimmune response disordersneurological disorderspsychiatric disordersrespiratory diseasesfibrosishepatic diseasesrenal diseasesdiseases of the pancreasmetabolic diseasesgenetic conditionscancerinfectious diseases and cardiovascular diseases; medical and veterinary preparations for therapeutic purposes for the treatment and prevention of ophthalmological conditionshearing losshematologic diseasesimmune response disordersneurological disorderspsychiatric disordersrespiratory diseasesfibrosishepatic diseasesrenal diseasesdiseases of the pancreasmetabolic diseasesgenetic conditionscancerinfectious diseases and cardiovascular diseases; biologicalchemical and biochemical reagents for medical use; DNARNAoligonucleotidespolynucleotides for medical use; gene editing enzymes for medical use; medical preparations containing therapeutic DNA and RNAnucleic and sequences for medical purposes; all of the foregoing excluding dietary and nutritional supplements
Classe 42
Scientific and technological services and research and design relating thereto namely scientific research services in the field of genomics; medical research services including the manipulation of biological reagents to be used for medical or therapeutic purposes; chemical and biological analysis and research services; scientific research into DNA and RNA; research and development into the creation of DNA and RNA; research and development services in the manufacture of synthetic DNARNAgenes and oligonucleotides for others; researchdevelopmenttesting and analysis for scientific research purposes in the field of genomicsDNA and RNA sequencinggene synthesisgene identificationgene cloninggene expressiongene mapping; scientific research in the field of molecular biologynext generation sequencinghigh-throughput sequencing and bioinformatics; gene-editing services for scientific research purposes; DNA and RNA modelling servicesgenetic mapping for scientific research purposes; gene engineering services; research and development services in the creation of genome libraries and collections of biologicals including chemicals and compounds; research and development services in creating libraries and collections of normal and mutated genes; scientific services research relating to the discoverypreclinical and clinical development of therapeutic productstherapeutic DNA and RNA; consultancy and advisory services relating to the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
35 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/03/2026
FIMP
FINAL DISPOSITION PROCESSED
02/03/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/12/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
19/11/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/11/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
19/11/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/08/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
19/08/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/06/2025
PUBO
PUBLISHED FOR OPPOSITION
03/06/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/05/2025
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
06/05/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/04/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/04/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
02/04/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/04/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
21/03/2025
DOCK
ASSIGNED TO EXAMINER
19/03/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/03/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/03/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/03/2025
DOCK
ASSIGNED TO EXAMINER
30/11/2024
RFNT
REFUSAL PROCESSED BY IB
07/10/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
16/09/2024
RFRR
REFUSAL PROCESSED BY MPU
16/09/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/09/2024
CNRT
NON-FINAL ACTION WRITTEN
12/09/2024
DOCK
ASSIGNED TO EXAMINER
09/09/2024
MAFR
APPLICATION FILING RECEIPT MAILED
24/06/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/06/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
20/06/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HARNESS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.